Frontotemporal lobar degeneration represents 10-20% of all dementias and is clinically important because of its earlier age of onset compared to Alzheimer's disease (AD), and its dramatic impact on core human qualities including personality, insight and verbal communication. We recently found that loss-of- function mutations in the gene encoding the secreted growth factor progranulin (PGRN) are an important cause of the most common pathological subtype of FTLD, characterized by neuronal inclusions composed of ubiquitinated TAR DNA-binding protein 43 (TDP43) (FTLD-U). Our working hypothesis is that mutations in PGRN are a more frequent cause of FTLD then initially anticipated and that subtle deregulation of PGRN expression may increase the susceptibility to develop FTLD and a wider range of neurodegenerative diseases. The identification of TDP43 as the pathological protein, not only in FTLD-U, but also in patients with amyotrophic lateral sclerosis (ALS) and in 20-30% of pathologically confirmed AD patients, supports a unifying disease mechanism underlying these disorders.
The specific aims of this project are to: 1. Identify the complete spectrum and frequency of mutations in PGRN. In the largest collection of FTLD patients worldwide, we will perform a standardized in- depth mutation screening of PGRN, supplemented with in-vitro functional analyses to determine the disease significance of novel mutations. 2. Identify regulatory cis-acting variants in PGRN that modify disease risk, penetrance or presentation in TDP43 proteinopathies. We will perform genetic association studies of PGRN in FTLD, ALS and AD case-control populations and assess the effect of common PGRN genetic variability on gene expression. 3. Determine the role of miR-659 expression and genetic variability in the development of FTLD. We recently made significant progress in the understanding of the regulation of PGRN when we identified that its expression can be regulated by a specific micro RNA, miR-659. Moreover, we have generated preliminary data suggesting that the common genetic variant rs5848, located in the 3'UTR of PGRN in a predicted binding-site for miR-659, is a major risk factor for FTLD-U through the augmented suppression of PGRN by miR-659. We will perform genetic and expression analyses to determine if deregulation of miR-659 expression in brain or altered genetic variability in the gene encoding miR-659 may contribute directly to the pathogenesis of FTLD-U The proposed studies are relevant to fully appreciate the contribution of PGRN mutations in FTLD leading to increased diagnostic accuracy and counseling. Unveiling the genetic and molecular pathways regulating PGRN may also reveal novel targets that can be exploited for therapeutic actions aimed at delaying the neurodegenerative disease process.

Public Health Relevance

This proposal is designed to define the complete PGRN mutational spectrum in FTLD and to determine whether subtle deregulation of PGRN expression may hold susceptibility to a wider range of neurodegenerative diseases. These studies are relevant to fully appreciate the contribution of PGRN mutations in FTLD leading to increased diagnostic accuracy and counseling. Unveiling the genetic and molecular pathways regulating PGRN may also reveal novel therapeutic targets that can be exploited for therapeutic actions aimed at delaying the neurodegenerative disease process.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS065782-02
Application #
7846733
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Sutherland, Margaret L
Project Start
2009-06-01
Project End
2013-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
2
Fiscal Year
2010
Total Cost
$331,341
Indirect Cost
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Popuri, Karteek; Dowds, Emma; Beg, Mirza Faisal et al. (2018) Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. Neuroimage Clin 18:591-598
Taskesen, E; Mishra, A; van der Sluis, S et al. (2017) Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci Rep 7:8899
Whitwell, J L; Boeve, B F; Weigand, S D et al. (2015) Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol 22:745-52
Nakamura, Masataka; Bieniek, Kevin F; Lin, Wen-Lang et al. (2015) A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. Acta Neuropathol 130:145-57
Tacik, Pawel; DeTure, Michael; Lin, Wen-Lang et al. (2015) A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathol 130:199-214
Kertesz, A; Finger, E; Murrell, J et al. (2015) Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase 21:178-84
Hallam, Bradley J; Jacova, Claudia; Hsiung, Ging-Yuek R et al. (2014) Early neuropsychological characteristics of progranulin mutation carriers. J Int Neuropsychol Soc 20:694-703
van Blitterswijk, Marka; Mullen, Bianca; Heckman, Michael G et al. (2014) Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging 35:2421.e13-7
Lee, Wing C; Almeida, Sandra; Prudencio, Mercedes et al. (2014) Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet 23:1467-78
van Blitterswijk, Marka; Mullen, Bianca; Nicholson, Alexandra M et al. (2014) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 127:397-406

Showing the most recent 10 out of 86 publications